GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » Shiller PE Ratio

TOVX (Theriva Biologics) Shiller PE Ratio : (As of Apr. 28, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Theriva Biologics Shiller PE Ratio Historical Data

The historical data trend for Theriva Biologics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics Shiller PE Ratio Chart

Theriva Biologics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Theriva Biologics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Theriva Biologics's Shiller PE Ratio

For the Biotechnology subindustry, Theriva Biologics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Shiller PE Ratio falls into.


;
;

Theriva Biologics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Theriva Biologics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Theriva Biologics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-1.598/133.1571*133.1571
=-1.598

Current CPI (Dec. 2024) = 133.1571.

Theriva Biologics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -1,487.522 99.621 -1,988.275
201506 -1,662.525 100.684 -2,198.733
201509 -1,050.016 100.392 -1,392.718
201512 -1,057.996 99.792 -1,411.728
201603 -1,050.016 100.470 -1,391.625
201606 -875.013 101.688 -1,145.800
201609 -799.330 101.861 -1,044.919
201612 -177.371 101.863 -231.863
201703 -175.003 102.862 -226.545
201706 -262.504 103.349 -338.216
201709 -1,225.000 104.136 -1,566.395
201712 192.500 104.011 246.442
201803 -162.500 105.290 -205.510
201806 -290.000 106.317 -363.212
201809 -232.500 106.507 -290.677
201812 -240.860 105.998 -302.574
201903 -62.500 107.251 -77.597
201906 -57.500 108.070 -70.848
201909 -77.500 108.329 -95.262
201912 -47.500 108.420 -58.338
202003 -50.000 108.902 -61.136
202006 -45.000 108.767 -55.091
202009 -35.000 109.815 -42.440
202012 -35.000 109.897 -42.408
202103 -32.500 111.754 -38.724
202106 -6.000 114.631 -6.970
202109 -6.250 115.734 -7.191
202112 -9.750 117.630 -11.037
202203 -7.750 121.301 -8.507
202206 -7.000 125.017 -7.456
202209 -7.500 125.227 -7.975
202212 -11.000 125.222 -11.697
202303 -7.500 127.348 -7.842
202306 -8.500 128.729 -8.792
202309 -4.850 129.860 -4.973
202312 -8.100 129.419 -8.334
202403 -7.500 131.776 -7.579
202406 -10.750 132.554 -10.799
202409 -6.810 133.029 -6.817
202412 -1.598 133.157 -1.598

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Theriva Biologics  (AMEX:TOVX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Theriva Biologics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics Business Description

Traded in Other Exchanges
N/A
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Executives
Steven A Shallcross director, officer: CEO and CFO C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro officer: Chief Operating Officer 9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan director
Scott Tarriff director 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman officer: CHIEF MEDICAL OFFICER 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp 10 percent owner 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne officer: CHIEF FINANCIAL OFFICER 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks director C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr director, officer: CEO & President C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome officer: Chief Scientific Officer 3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman director
Wayne George Holman 10 percent owner 430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022

Theriva Biologics Headlines